Asset Manager

Updated:

HJ Capital

HJ Capital was founded in 2015 as the venture capital subsidiary of Baomao Group. Baomao Group conducts equity investments, securities investments, green...

HJ Capital logo

HJ Capital

HJ Capital was founded in 2015 as the venture capital subsidiary of Baomao Group. Baomao Group conducts equity investments, securities investments, green finance, and asset management. The firm pursues early-stage seed and start-up rounds as well as expansion and late-stage opportunities. Asset classes include venture equity and direct holdings. Geographic reach centers on China with additional exposure through Atrium Medical Biosurgery Business in the United States. Confirmed co-investors include GDD Industry Fund in medical and technology deals. AUM sits at an estimated $230 million. The firm lists two commercial real-estate holdings: Anhui Zhucheng Real Estate Co., Ltd. and Beijing Capital Airport Property Management Co., Ltd. No dated operational events from the last 24 months appear in available records. HJ Capital functions strictly as a venture subsidiary rather than an independent family office or multi-strategy manager. Investment decisions remain tied to Baomao Group oversight.

General information

Firm type

Generalist

Year founded

2015

AUM

$230M (Altss estimate)

Location

Region

Asia

Country

China

City

Shanghai

Corporate office

Shanghai, China

Principals

Yang Xiao

Managing Director

Sector focus

Venture Capital

Frequently asked questions

Who runs investment decisions at HJ Capital?

Yang Xiao holds the title of Managing Director. Decisions occur within the structure of Baomao Group.

Does HJ Capital participate in fund commitments or only direct deals?

The firm executes direct venture investments and co-investments. No fund commitments are recorded.

What investment stages does HJ Capital typically target?

Early-stage seed, start-up, and expansion or late-stage rounds form the core focus.

Where does HJ Capital maintain its primary operations?

Headquarters are in Shanghai, China, with portfolio exposure extending to the United States via Atrium Medical.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Shanghai Generalist profiles